Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Nykode Therapeutics ASA Remuneration Information 2021

Jun 3, 2021

3695_dirs_2021-06-03_8bdad83c-9ba3-4482-b88e-1e92e484fc93.html

Remuneration Information

Open in viewer

Opens in your device viewer

Grant of Restricted Share Units and Share Options

Grant of Restricted Share Units and Share Options

Oslo, Norway, June 3, 2021 - Reference is made to the Annual General Meeting of Vaccibody AS on May 5, 2021, where the issuance of Restricted Share Units (RSUs) to the new board member Birgitte Volck was approved. Birgitte Volck has been granted 4,674 RSUs in line with the terms set out in the minutes from the Annual General Meeting.

Further, 200,000 share options have been granted to Mikkel Wandahl Pedersen in connection with his appointment as Chief Scientific Officer. The share options will have a strike price of NOK 81.14 per share, have a five-year term and will vest equally over a four-year vesting period. After the award of the share options, Mikkel Wandahl Pedersen holds a total of 200,000 share options and 0 shares.

Please see further details in attached document.